[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Edoxaban - Potential Game changer in oral anticoagulant market

August 2012 | 64 pages | ID: EA10DC508E2EN
MP Advisors

US$ 1,000.00

E-mail Delivery (PDF), Online Subscription, E-mail Delivery (Word)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
1. EXECUTIVE SUMMARY

Market Model for Stroke Prevention in Atrial Fibrillation and DVT
Treatment
Why is Edoxaban a potential Mega Blockbuster
Edoxaban –Market potential
  Indication wise
  Geography wise
  Compared to other oral next generation anticoagulants
Our view on key upcoming Milestones For Edoxaban and Factor Xa class
Estimated launch timelines for new generation anticoagulants–Indication wise/Geographywise

2. EDOXABAN IN SPAF

Background information on Edoxaban (Lixiana)
Edoxaban PK/PD data comparision to other novel oral anticoagulant
Expectations from ENGAGE AF study
  ENGAGE AF Clinical trial design comparison to other Clinical trial designs
  Analysis of chronology of events happened in completion of ENGAGE AF
Analysis of the reported clinical trial results of Edoxaban
  PhII data in Japanese Patient pool
  PhII data in Global Patient Pool
  PhII data in Taiwan patient pool
Japan- PhII/III clinical data comparision of Edoxaban with other oral anticoagulants
Relative clinical profile and Positioning of Edoxaban compared to Xarelto, Eliquis and Pradaxa in different geographies

3. EDOXABAN MARKET POSITIONING IN SPAF, MARKET MODEL AND PEAK SALES

Estimates based on:
Switch From Warfarin
  Warfarin continues to hold itself strong against Pradaxa and
Xarelto– Will the entry of Eliquis / Edoxaban change the scenario?
Switch from Aspirin
Switch/Addition to those on dual antiplatelets
Geographywise clinical data difference and different clinical practise
results in different market leader/market share
Risk to our market share Forecast

4. FACTORS THAT WILL RESTRICT ADOPTION OF NEW GENERATION ORAL

Anticoagulants post launch
Experts view on the hurdles to the adoption of new generation anticoagulants in SPAF at ESC-12
Concomitant Medicines- Donut hole and drug-drug interaction
Availability of antidote for novel oral anticoagulants
Regulatory Scenario – Medicare Shared Saving program to be implemented in 2012
Reimbursement status of PT/INR monitoring for warfarin in major countries
Warfarin Genotype testing, its regulatory approval and its reimbursement

5. EDOXABAN IN VTE TREATMENT

Market potential
  Treatment duration
  Geographywise Prevalence
Edoxaban Clinical Profile compared to Other Factor Xa inhibitor in VTE treatment
  Results from PhII BOTTICELI study of Eliquis
  Expected data from HOKUSAI VTE study
Pros and Cons of Edoxaban market potential in VTE treatment

ANNEXURE - 1: ANALYSIS OF THE REPORTED PIVOTAL CLINICAL STUDY RESULTS OF NEXT GENERATION ORAL ANTICOAGULANTS (PRADAXA, ELIQUIS, AND XARELTO) IN SPAF

Efficacy and Safety comparision of ROCKET AF, RELY ARISTOTLE AND AVERROES
ROCKET AF, ARISTOTLE & RELY - Cross Trial Comparison Based On CHADS2 Score
ROCKET AF, ARISTOTLE , AVERROES & RELY – Efficacy and Safety comparison – subgroup analysis
GEOGRAPHYWISE NET CLINICAL BENEFIT COMPARISON- Eliquis, Xarelto, Paradaxa

ANNEXURE - 2 ANALYSIS OF THE REPORTED CLINICAL DATA IN VTE TREATMENT

Prolongation of VTE treatment Duration with Xarelto and Pradaxa
Clinical data comparison of Xarelto, Eliquis and Paradaxa in VTE treatment


More Publications